Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

3 Months Ended

Mar. 31, 2023

12. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the three months ended March 31, 2023:



	Three Months Ended March 31,
	2023	2022
Warrants to purchase Common Stock	1,909,450	4,505,621
Options to purchase Common Stock	622,629	820,990
Unvested Restricted Stock	20,699,016	18,710,303
Unvested Restricted Stock Units	1,065	103,832
Total	23,232,160	24,140,746